Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

  • EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1
     
  • If approved, Cosentyx would become the first fully-human IL-17A inhibitor indicated for patients in Europe with nr-axSpA
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US, which forms part of the axial spondyloarthritis (axSpA) disease spectrum2
     
  • Cosentyx is …
/by

AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

  • Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene
     
  • Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in presymptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones unseen in natural history of the disease and to date …
/by

Visualizing molecular glues

Every cell in the human body is packed with proteins. These large molecules float around, bump into one another and make the stuff of life happen. They turn fuel into energy. They dispose of trash. They read genetic codes and coax cells to divide.

In some cells, naturally occurring “molecular glues” float among these proteins. Like crafty matchmakers, these small molecules stick proteins together. By doing so, they may change a cell’s destiny.

Drug hunters at the Novartis Institutes for BioMedical Research (NIBR) think these tiny matchmakers also have the potential to change …

/by